Other functions: preclinical in vitro and in vivo agent devlepment assays - blood-based biomarkers of obesity-induce breast inflammation
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8 Part of Cornell University
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $614,987
Award facts
- Contract value 100% obligated
- $614,987.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$29,025 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $644,012 |
About this award
This is a delivery order under the Preclinical Agent Development Assays 2012-2016 Indefinite Delivery Contract (IDC) awarded by the National Cancer Institute (NCI) to the Weill Medical College of Cornell University. The order is for $614,987.25 and covers preclinical in vitro and in vivo agent development assays and blood-based biomarkers of obesity-induced breast inflammation. This work supports the NCI's PREVENT Cancer Preclinical Drug Development Program, which aims to transition cancer preventive agents from discovery to clinical trials. As a subcontractor, Memorial Sloan Kettering Cancer Center will provide anonymized serum samples from breast cancer patients to support the metabolic profiling research. The contract does not have a set-aside designation. Weill Medical College of Cornell University, a prestigious private research university, has a strong track record of securing significant federal funding from agencies like the NIH to advance biomedical research and medical innovations.
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on September 20, 2012.
How much is contract HHSN26100003 worth?
The government has obligated $614,987 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201200018I, an indefinite delivery contract, on Preclinical Agent Development Assays 2012-2016.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award